New injection shows promise for relieving intense itching
NCT ID NCT06424470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether Stapokibart injection can reduce severe itching and skin bumps in adults with prurigo nodularis. About 200 participants will receive either the drug or a placebo for 24 weeks. The main goal is to see if itching improves by at least 4 points on a 0-10 scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stapokibart injection
What this could lead to
If successful, this could provide a new treatment option to reduce severe itching and clear skin nodules in people with prurigo nodularis.
What could go wrong
This is a single Phase 3 trial with 200 participants. Results may not apply to everyone, and side effects or lack of benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRURIGO NODULARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of China Medical University
Shenyang, Liaoning, China